DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission

Not Applicable

Not yet recruiting

Conditions: Ulcerative Colitis (UC)

First Posted Date: 2024-11-18

Last Posted Date: 2025-05-04

Lead Sponsor: University of Chicago

Target Recruit Count: 200

Registration Number: NCT06693310

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use

Not Applicable

Conditions: Substance Use Disorders
Hiv

First Posted Date: 2024-11-12

Last Posted Date: 2025-02-25

Lead Sponsor: University of Chicago

Target Recruit Count: 900

Registration Number: NCT06682468

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Phase 2

Not yet recruiting

Conditions: Carcinoma, Squamous Cell
Anorectal Cancer

Interventions: Drug: Pembrolizumab
Drug: Lenvatinib

First Posted Date: 2024-11-01

Last Posted Date: 2025-02-07

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT06669572

Locations: 🇺🇸
o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Neuroendocrine Tumor

Interventions: Drug: Fulvestrant
Drug: 177Lu-DOTATATE

First Posted Date: 2024-10-29

Last Posted Date: 2024-12-27

Lead Sponsor: University of Chicago

Target Recruit Count: 25

Registration Number: NCT06663072

Locations: 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Phase 4

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Darolutamide
Drug: Physician choice Androgen Deprivation (Hormone) Therapy

First Posted Date: 2024-10-28

Last Posted Date: 2024-10-28

Lead Sponsor: University of Chicago

Target Recruit Count: 80

Registration Number: NCT06660862

Locations: 🇺🇸
o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Does Ethyl Chloride Spray Work?

Not Applicable

Not yet recruiting

Conditions: Injection Fear
Injection Pain Prevention
Injection Complication

First Posted Date: 2024-10-22

Last Posted Date: 2025-04-09

Lead Sponsor: University of Chicago

Target Recruit Count: 300

Registration Number: NCT06651788

Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA

Recruiting

Conditions: Lymphatic Reconstruction

First Posted Date: 2024-10-21

Last Posted Date: 2025-01-14

Lead Sponsor: University of Chicago

Target Recruit Count: 90

Registration Number: NCT06650592

Locations: 🇺🇸
The University o Chicago, Chicago, Illinois, United States

Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau

Phase 1

Recruiting

Conditions: Tibial Plateau Fractures

Interventions: Drug: Bupivacain

First Posted Date: 2024-10-15

Last Posted Date: 2025-01-14

Lead Sponsor: University of Chicago

Target Recruit Count: 38

Registration Number: NCT06639503

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain

Phase 2

Recruiting

Conditions: Nephrolithiasis

Interventions: Other: Normal saline
Drug: Bupivacaine

First Posted Date: 2024-10-10

Last Posted Date: 2025-01-14

Lead Sponsor: University of Chicago

Target Recruit Count: 116

Registration Number: NCT06635889

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

Immune Status After Being on Call for 24 Hrs

Recruiting

Conditions: Sleep Deprivation

Interventions: Diagnostic Test: Blood Sample Collection
Device: Actigraph (GT9X-BT) Monitor

First Posted Date: 2024-10-10

Last Posted Date: 2024-10-26

Lead Sponsor: University of Chicago

Target Recruit Count: 60

Registration Number: NCT06636318

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy